OncoSignal
Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Glioblastoma

IDH-wildtype disease that almost always recurs: EGFR, the blood-brain barrier and cell therapy attempts.

Live from ClinicalTrials.gov and PubMed, fetched 2026-11-11 15:10 UTC. Every row links to its source record.

Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.

Phase advances
1
since 2026-07-14
New Ph2+ trials
6
Results posted
3
Readouts due
16
primary completion reached
Trial papers
15
PubMed, last 60 days
  1. New trial
    New Ph1 trial: NCT07929909

    Beijing Inno Medicine Co., Ltd.. A Phase I Clinical Study of YN003 in the Treatment of Glioma

  2. New trial
    New Ph1 trial: NCT07927491

    NYU Langone Health. Surgical Window Study of CM93 in Subjects With Recurrent Glioblastoma (rGBM)

  3. New trial
    New Ph1 trial: NCT07909811

    Unity Health Toronto. Novel endOvascular Therapy With beVAcizumab and Cannabinoids for Glioblastoma

  4. Readout due
    Readout due: hSTAR GBM reached primary completion

    Leland Metheny. hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

  5. Readout due
    Readout due: NANO-GBM reached primary completion

    Centre Jean Perrin. AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

  6. Readout due
    Readout due: NCT03743662 reached primary completion

    Memorial Sloan Kettering Cancer Center. Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

  7. Readout due
    Readout due: NCT05734560 reached primary completion

    Darell Bigner. D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

  8. Readout due
    Readout due: STAR-GBM reached primary completion

    Myosin Therapeutics Inc.. A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

  9. Results posted
    Results posted: NCT02137759

    MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

  10. Results posted
    Results posted: NCT04590664

    Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

  11. New trial
    New Ph1/Ph2 trial: ALERT-1 (NCT07902037)

    Siren Biotechnology. A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)

  12. Results posted
    Results posted: NCT04019002

    Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma

  13. Paper
  14. New trial
    New Ph2 trial: STAR-VACC (NCT07888647)

    German Cancer Research Center. IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas

  15. Paper
  16. Paper
  17. Paper
  18. New trial
    New Ph2/Ph3 trial: CAR-T (NCT07873996)

    Beijing Tiantan Hospital. Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma

  19. Paper
  20. Readout due
    Readout due: NCT06521567 reached primary completion

    GlaxoSmithKline. A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

  21. Paper
  22. Paper
  23. Readout due
    Readout due: AFGBMBiop reached primary completion

    Peter Siesjö. Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma

  24. Readout due
    Readout due: NCT04094610 reached primary completion

    Turning Point Therapeutics, Inc.. A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

  25. Readout due
    Readout due: NCT05986851 reached primary completion

    Cantex Pharmaceuticals. Azeliragon in MGMT Unmethylated Glioblastoma

  26. Paper
  27. Paper
  28. Paper
  29. Readout due
    Readout due: NCT04049669 reached primary completion

    Theodore S. Johnson. Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

  30. Paper
  31. Paper
  32. Paper
  33. Paper
  34. Readout due
    Readout due: NCT05465954 reached primary completion

    Mayo Clinic. Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

  35. Readout due
    Readout due: NCT05607407 reached primary completion

    Case Comprehensive Cancer Center. Methimazole in Patients With Progressive Glioblastoma

  36. Readout due
    Readout due: NCT06147505 reached primary completion

    Dushu Lake Hospital Affiliated to Soochow University. XS005 Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)

  37. Readout due
    Readout due: NCT04752813 reached primary completion

    BPGbio. A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

  38. Readout due
    Readout due: NCT05183204 reached primary completion

    Weill Medical College of Cornell University. Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma

  39. Readout due
    Readout due: NCT04863950 reached primary completion

    The University of Texas Health Science Center at San Antonio. Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

  40. Phase advance
    EGFR/EGFRvIII Inhibitor WSD0922-FU advances to Ph2 (indication level)

    Mayo Clinic posted NCT07708961: Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

  41. Paper

A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.